Ahmed Z Obeidat
Overview
Explore the profile of Ahmed Z Obeidat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
170
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abboud H, Subei A, Sengul B, Shin R, Goulette P, Walch R, et al.
Front Immunol
. 2025 Jan;
15:1526563.
PMID: 39867894
Objectives: This case series describes adults with aquaporin 4 immunoglobulin G-seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD) who switched treatment from eculizumab to satralizumab. Methods: Case information for patients with...
2.
Gurski C, Hajiyeva Z, Veltri A, Fenton K, ODell S, Obeidat A, et al.
J Neuroimmunol
. 2024 Dec;
399:578519.
PMID: 39731832
No abstract available.
3.
Gurski C, Hajiyeva Z, Veltri A, Fenton K, ODell S, Obeidat A, et al.
J Neuroimmunol
. 2024 Dec;
399:578502.
PMID: 39643951
In multiple sclerosis (MS) the B cell depleting drug ocrelizumab has shown high efficacy in reducing inflammatory activity. Its mechanism of action is unclear due to B cell subset complexity...
4.
Nerenz R, Hooshmand S, Jackowiak E, Shirilla D, Yang Y, Yang K, et al.
Am J Clin Pathol
. 2024 Sep;
163(1):109-120.
PMID: 39255415
Objectives: Selection of autoimmune/paraneoplastic antibody panels remains challenging because health-care professionals often lack familiarity with panel contents, recommended specimen types, and antibody combinations for a given patient. Inappropriate use adds...
5.
6.
Porwal M, Razzak A, Kumar V, Obeidat A, Sharma U
Epilepsy Res
. 2024 May;
203:107382.
PMID: 38761467
Background: Pharmacovigilance systems such as the FDA Adverse Event Reporting System (FAERS), are established models for adverse event surveillance that may have been missed during clinical trials. We aimed to...
7.
Peters J, Cohen J, Corboy J, Hopkins S, Hua L, Kakara M, et al.
Neurol Educ
. 2024 May;
1(1).
PMID: 38725979
Introduction And Problem Statement: Neuroimmunology is a rapidly evolving subspecialty. At this time, fellowship training is not standardized. Discrepancies exist in fellowship programs across the United States, including in faculty...
8.
Gomez Hjerthen I, Hacker C, Meador W, Obeidat A, Horta L, Mateen F
Ann Clin Transl Neurol
. 2024 Feb;
11(4):1011-1020.
PMID: 38374778
Background And Objectives: We aim to characterize the sociodemographic and clinical factors associated with loss of jobs, income, and work hours in people with neuromyelitis optica spectrum disorder (NMOSD) in...
9.
Razzak A, Hernandez R, Salter A, Obeidat A
Mult Scler Relat Disord
. 2024 Jan;
83:105438.
PMID: 38242052
Background: Studies have suggested possible multiple sclerosis (MS) prodrome with non-routine healthcare utilization as an indicator. The objective of this project was to compare utilization in the four years (years...
10.
Obeidat A
Mult Scler Relat Disord
. 2023 Dec;
82:105389.
PMID: 38118288
Prof. Kurtzke once said, "Multiple sclerosis is what a good clinician would call multiple sclerosis." Recent McDonald's diagnostic criteria revisions have allowed for earlier diagnoses over the past decades. Revisions...